Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the latest version of the OmniTom Elite system, which has been enhanced with photon-counting CT (PCCT) technology.
The PCCT-optimized features of the device range from advanced image processing and an expanded scope of scanning to helical scanning capability, according to NeuroLogica, a subsidiary of Samsung that manufactures the OmniTom Elite system.
The enhanced OmniTomElite computed tomography (CT) system offers a variety of photon-counting CT features including an ultra-high resolution mode with 0.141 mm resolution and expanded scanning to capture a 30 cm field of view. (Image courtesy of NeuroLogica.)
NeuroLogica said key benefits include access to 0.141 mm resolution with the system’s ultra-high resolution mode, post-reconstruction features such as bone removal and virtual non-contrast, continuous spiral scanning capability and expanded scanning to capture a 30 cm field of view.
“With these new features, the OmniTom® Elite PCD not only offers exquisite image quality and diagnostic capabilities but also ensures a more versatile and efficient imaging process. This is a significant advancement for point-of-care imaging, continuing our commitment to enable clinicians to make a more confident diagnosis due to the improved clinical information,” noted Renaud Maloberti, the vice president and head of mCT business at NeuroLogica.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.